Moleculin Biotech Inc (MBRX)

[BooDog]

MBRX's licensee WPD Pharma Research Shows WP1122 Could Reduce Replication of Covid-19 Virus
8:50 AM ET 4/9/20 | Dow Jones
Related Quotes

MBRX
Price$1.17 Day's Change -0.105 (-8.27%) Bid 1.16 Ask 1.17
B/A Size 35900x6600 Day's High 1.43Day's Low1.14
Volume (Heavy Day)
23,943,617
April 09, 2020 1:09pm ET

WCOTF
Price$1.25 Day's Change

0.55 (78.57%) Bid 1.24 Ask 1.32B/A Size 1000x2000



By Chris Wack

WPD Pharmaceuticals Inc. said Thursday that independent research on its WP1122 drug compound found 2-deoxy-D-glucose to reduce replication of SARS-CoV-2, the virus that causes Covid-19, by 100% in in vitro testing.

WPD said it would collaborate with its development partner CNS Pharmaceuticals Inc. to develop several preclinical drug candidates including WP1122, which will be tested on a range of viruses including the coronavirus SARS-CoV-2.

WPD has licensed rights to a portfolio of drug candidates, including WP1122, through its license partner, Moleculin Biotech Inc.

"We are excited with this breakthrough on our WP1122 drug candidate and the early implications are that it could have positive effects on reducing the spread of Covid-19," commented Mariusz Olejniczak, chief executive of WPD.

CNS Pharma shares were up 18%, to $3.25, in premarket trading. Moleculin Biotech shares were up 5%, to $1.34.

Write to Chris Wack at [e-mail]

> Dow Jones Newswires

April 09, 2020 08:50 ET (12:50 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.



https://investorshub.advfn.com/boards/read_msg.aspx?message_id=154915432